GlobeNewswire by notified

Statkraft inngår avtale med FREYR Battery for langsiktig forsyning av fornybar energi

Del

(New York, Oslo og Luxembourg, 25. mai 2022) Statkraft, Europas største produsent av fornybar energi har inngått en bindende prinsippavtale med FREYR Battery (NYSE: FREY) (“FREYR”), en utvikler av ren, neste-generasjons produksjonskapasitet for battericeller. Prinsippavtalen ventes å bli ferdigstilt som en langsiktig kraftkjøpsavtale (PPA), med sikte på å sikre langsiktig forsyning av fornybar energi til globalt konkurransedyktige vilkår for FREYRs planlagte battericellefabrikker i Mo i Rana, Norge.

Avtalen og tilknyttede energitjenester levert av Statkraft, anslås å dekke hele det forventede strømbehovet i perioden 2024-2031 og sikre fysisk leveranse av kraft fra sentralnettet i Mo i Rana til FREYRs pilotfabrikk og den første planlagte gigafabrikken. Statkraft forplikter seg til å levere inntil 23 MW grunnlast med et samlet volum i kontraktsperioden på 1,4 TWh, sammen med opprinnelsesgarantier som dokumenterer at kraften kommer fra Statkrafts vannkraftproduksjon i regionen.

- Vår ambisjon er å lage rene battericeller og et sentralt element i vår strategi er å produsere med fornybar energi. Denne avtalen med Statkraft sikrer at våre produksjonsanlegg i Mo i Rana får en jevn, langsiktig forsyning av vannkraft fra lokale kilder og holder vårt karbonavtrykk på et minimum når vi går over i full drift, sier Tove Nilsen Ljungquist, EVP Operations i FREYR.

- Statkraft bidrar til det grønne skiftet ved å levere fornybar kraft til eksisterende kunder og nye industriaktører over hele verden. Vi er glade for å bidra til etableringen av FREYRs battericelleanlegg i Nord-Norge, som muliggjør grønne arbeidsplasser og bruk av lokale kraftressurser. Sammen med fleksibel vannkraft er batterier helt avgjørende for å nå målene om netto nullutslipp, sier EVP Market & IT i Statkraft, Hallvard Granheim.

Ifølge prinsippavtalen skal Rana vannkraftverk forsyne FREYRs fabrikker med fornybar energi. Kraftverket er 100% eid av Statkraft med en kapasitet på 500 MW og en årlig produksjon på cirka 2 150 GWh. Nærheten mellom vannkraftverket og FREYRs planlagte produksjonsanlegg i Mo i Rana er i tråd med FREYRs ambisjon om å etablere virksomhet i områder med god lokal tilgang på ren energi.

***

Om Statkraft

Statkraft er et ledende internasjonalt selskap innen vannkraft og Europas største leverandør av fornybar energi. Konsernet produserer vannkraft, vindkraft, solkraft og gasskraft og leverer fjernvarme. Statkraft er en global markedsaktør innen energihandel og har 4800 ansatte i 19 land.

Om FREYR Battery

FREYR Batterys ambisjon er å tilby rene batteriløsninger i industriell skala for å redusere globale utslipp. New York Stock Exchange-noterte FREYR har som misjon å akselerere avkarboniseringen av verdens energi- og transportsystemer. FREYR er i gang med byggingen av den første av sine planlagte fabrikker i Mo i Rana og har annonserte planer for mulig utvikling av industriell battericelleproduksjon i Vaasa, Finland og USA. FREYR planlegger å ha opptil 43 GWh battericellekapasitet i 2025 og opptil 83 GWh i årlig kapasitet i 2028. For å lære mer om FREYR, vennligst besøk www.freyrbattery.com

Investorkontakt:

Jeffrey Spittel
Vice President, Investor Relations
jeffrey.spittel@freyrbattery.com
Tel: (+1) 281-222-0161

Mediakontakt:

Katrin Berntsen
Vice President, Communication and Public Affairs
katrin.berntsen@freyrbattery.com
Tel: (+47) 920 54 570

Lars Magnus Günther
Pressetalsperson Statkraft AS
lars.gunther@statkraft.com
Tel: (+47) 912 41 636


Cautionary Statement Concerning Forward-Looking Statements

All statements, other than statements of present or historical fact included in this press release, including, without limitation, statements regarding (i) any potential benefits from the long-term physical supply agreement, including Statkraft’s supply and timely delivery of electricity sourced from renewable energy assets under competitive terms, (ii) the development, timeline, capacity, and other usefulness of FREYR’s planned battery cell production plants and battery development strategy and (iii) FREYR’s ambition and ability to establish operations with renewable energy from local sources and keep its carbon footprint to a minimum are forward-looking and involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.

Most of these factors are outside FREYR’s control and difficult to predict. Information about factors that could materially affect FREYR is set forth under the “Risk Factors” section in FREYR’s Registration Statement on Form S-1 filed with the Securities and Exchange Commission (the “SEC”) on August 9, 2021, as amended, and in other SEC filings available on the SEC’s website at www.sec.gov.


Vedlegg

Hvis du vil se dette innholdet fra www.globenewswire.com, gi ditt samtykke øverst på denne siden.
Hvis du vil se dette innholdet fra ml-eu.globenewswire.com, gi ditt samtykke øverst på denne siden.

Om GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg pressemeldinger fra GlobeNewswire by notified

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire by notified på epost fortløpende. Du kan melde deg av når som helst.

Siste pressemeldinger fra GlobeNewswire by notified

Report – ERYTECH’s Combined Shareholders’ Meeting On June 24, 202224.6.2022 22:05:00 CEST | Press release

REPORT –ERYTECH’S COMBINED SHAREHOLDERS’ MEETING ON JUNE 24, 2022 Cambridge, MA (U.S.) and Lyon (France), June24, 2022 – ERYTECH Pharma (Nasdaq& Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announcedthat its Annual General Meeting was held on Friday, June 24, 2022. At the meeting, all resolutions for which the Board of Directors recommended a vote in favor were adopted, including: Approval of the annual financial statements and consolidated financial statements for the year ended December 31, 2021;Allocation of the financial year's results;Approval of the statutory auditors’ special report on regulated agreements and commitments with related parties;Approval of the elements of total compensation and benefits paid or allocated for the year ended December 31, 2021, to Gil BEYEN, Chief Executive Officer and Jean-Paul KRESS, Chairman of the Board;Approval of the compens

Cleantech Building Materials: Results of Annual General Meeting24.6.2022 14:54:27 CEST | Press release

24 June 2022 CLEANTECH BUILDING MATERIALS PLC, NASDAQ FIRST NORTH GROWTH MARKET, COPENHAGEN TICKER: CBM ISIN: GBOOBD1LVD21 CLEANTECH BUILDING MATERIALS PLC Results of Annual General Meeting The Annual General Meeting (“AGM”) of Cleantech Building Materials plc (“CBM” or the “Company”) was held in London earlier today, 24 June 2022. Details of the resolutions to be considered at the AGM were published in the Notice of AGM which was posted to Shareholders on 1 June 2022 and is available on the Company’s website: www.cbm-plc.com. All resolutions as set out in the Notice of AGM were duly passed without discussion. In particular, the following resolutions were passed at the AGM. The AGM resolved to authorise the directors of the Company to allot shares and grant rights to subscribe for, or convert any security, into shares. The directors of the Company sought authority for the purposes of section 551 of the Companies Act to exercise all the powers of the Company to allot shares and grant ri

Novartis receives positive CHMP opinion for Scemblix®, a novel treatment for adult patients with chronic myeloid leukemia24.6.2022 13:13:19 CEST | Press release

With unique STAMP mechanism of action, Scemblix could provide a new option for patients in Europe with chronic myeloid leukemia (CML) who have suffered intolerance or inadequate response with at least two prior tyrosine kinase inhibitor treatments1 Positive opinion based on data from pivotal Phase III ASCEMBL trial, showing a near doubling in major molecular response rate for patients treated with Scemblix® (asciminib) vs. Bosulif®* (bosutinib) (25.5% vs. 13.2%) and more than three times lower discontinuation rate due to adverse reactions (5.8% vs 21.1%) at 24 weeks1 CHMP recommendation comes after the approval of Scemblix by the US FDA and other countries’ regulatory authorities, potentially broadening access for more patients to Novartis transformative therapies in CML Basel, June 24, 2022 — Novartis today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting marketing au

Clariant’s shareholders approve all agenda items24.6.2022 11:30:00 CEST | Press release

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Integrated Report and Group Consolidated Financial Statements for fiscal year 2021 approvedGünter von Au reelected as Chairman of the Board of DirectorsThree new candidates join the Board of Directors: Ahmed Mohamed Alumar, Roberto César Gualdoni, Naveena ShastriConfirmed distribution of CHF 0.40 per shareKPMG confirmed as statutory auditor from 2022 MUTTENZ, JUNE 24, 2022 Clariant, a focused, sustainable, and innovative specialty chemical company, today held its 27th Annual General Meeting (AGM) where the shareholders approved all agenda items and resolutions as proposed by the Board of Directors. The AGM was held virtually, where shareholders were able to exercise their rights exclusively via the independent proxy. Overall, 698'945'298 shares or around 70.19 % of the share capital of Clariant were represented. Günter von Au was reelected as Chairman of the Board of Directors. Additionally, three new members were voted to join by a large majo

Cool Company Ltd. – Mandatory Notification Of Trade24.6.2022 11:01:19 CEST | Press release

EPS Ventures Ltd., close associate of Cyril Ducau, Chair of the Board of Cool Company Ltd. (the “Company”), has on 23 June 2022 acquired 7,865 shares in the Company at a price of NOK 90.274882 per share. Following the transaction, EPS Ventures Ltd. holds a total of 15,591,218 shares in the Company, equivalent to 38.97% of the Company’s shares. Please see the attached notification form in accordance with the Market Abuse Regulation article 19. This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act Attachment Primary insider notification form